X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Intravacc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 29, 2020
Details:
Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Tel Aviv University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 13, 2020
Details:
The deal provides Neovii with the exclusive right to develop and commercialise a platform technology created by Biotechnology professor Jonathan Gershoni of TAU’s School of Molecular Cell Biology, to rapidly identify epitope-based vaccines.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
